Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av JNJ-90301900 i kombinasjon med kjemoradiasjon etterfulgt av konsoliderende immunterapi for ikke-småcellet lungekreft (NSCLC) (CONVERGE)

2. november 2026 oppdatert av: Johnson & Johnson Enterprise Innovation Inc.

En fase 2, randomisert, åpen etikett, aktivt kontrollert studie av JNJ-90301900 i kombinasjon med kjemoradiasjon etterfulgt av Durvalumab i lokalt avansert og ikke-opererbar stadium III NSCLC

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

130

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Camperdown, Australia, 2050
        • Rekruttering
        • Chris O'Brien Lifehouse
      • Herston, Australia, 4029
        • Rekruttering
        • Royal Brisbane and Women's Hospital
      • Nedlands, Australia, 6009
        • Rekruttering
        • Sir Charles Gairdner Hospital
      • North Ryde, Australia, 2109
        • Rekruttering
        • Macquarie University
      • Parkville, Australia, 3050
        • Rekruttering
        • Royal Melbourne Hospital
      • Barretos, Brasil, 14784 400
        • Rekruttering
        • Fundacao Pio XII
      • São Paulo, Brasil, 05651 901
        • Rekruttering
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brasil, 01308 050
        • Rekruttering
        • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
    • California
      • La Jolla, California, Forente stater, 92037
        • Rekruttering
        • Moores Cancer Center at UC San Diego Health
    • Connecticut
      • Farmington, Connecticut, Forente stater, 06030
        • Fullført
        • University of Connecticut Health Center
      • New Haven, Connecticut, Forente stater, 06519
        • Rekruttering
        • Yale University
    • Florida
      • Miami, Florida, Forente stater, 33136
        • Rekruttering
        • University of Miami
      • Orlando, Florida, Forente stater, 32806
        • Rekruttering
        • Orlando Health Cancer Institute
    • Georgia
      • Atlanta, Georgia, Forente stater, 30306
        • Rekruttering
        • Emory University Winship Cancer Institute
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Beth Israel Deaconess Medical Center
    • Missouri
      • St Louis, Missouri, Forente stater, 63130
        • Rekruttering
        • Washington University in St Louis
    • New Jersey
      • New Brunswick, New Jersey, Forente stater, 08901
        • Rekruttering
        • Rutgers Cancer Institute of New Jersey
    • New York
      • New York, New York, Forente stater, 10016
        • Rekruttering
        • NYU Langone Health
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27514
        • Rekruttering
        • University of North Carolina at Chapel Hill
      • Pinehurst, North Carolina, Forente stater, 28374
        • Rekruttering
        • FirstHealth of the Carolinas
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • Rekruttering
        • University Hospitals Cleveland Medical Center
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Rekruttering
        • Oregon Health And Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • University of Pennsylvania
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • MD Anderson Cancer Center
    • Vermont
      • Burlington, Vermont, Forente stater, 05401
        • Rekruttering
        • University of Vermont Medical Center
      • Brest, Frankrike, 29200
        • Rekruttering
        • Hopital De La Cavale Blanche
      • Marseille, Frankrike, 13015
        • Rekruttering
        • Hopital Nord Marseille
      • Paris, Frankrike, 75248
        • Rekruttering
        • Institut Curie
      • Paris, Frankrike, 75020
        • Rekruttering
        • Hopital Tenon
      • Rouen, Frankrike, 76000
        • Rekruttering
        • CHU Rouen Hopital Charles Nicolle
      • Villejuif, Frankrike, 94805
        • Rekruttering
        • Gustave Roussy
      • Shatin, Hong Kong
        • Rekruttering
        • Prince of Wales Hospital
      • Dongguan, Kina, 523109
        • Rekruttering
        • Dongguan People s Hospital
      • Guangzhou, Kina, 510080
        • Rekruttering
        • The First Affiliated Hospital Sun Yat sen University
      • Jinan, Kina, 250117
        • Rekruttering
        • The Affiliated Cancer Hospital of Shandong First Medical University
      • Amsterdam, Nederland, 1066 CX
        • Rekruttering
        • Antoni van Leeuwenhoek
      • Nijmegen, Nederland, 6525 GA
        • Rekruttering
        • Radboud Umcn
      • Madrid, Spania, 28041
        • Rekruttering
        • Hosp. Univ. 12 de Octubre
      • Pamplona, Spania, 31008
        • Rekruttering
        • Clinica Univ. de Navarra
      • Santiago de Compostela, Spania, 15706
        • Rekruttering
        • Hosp. Clinico Univ. de Santiago
      • Valencia, Spania, 46026
        • Rekruttering
        • Hosp. Univ. I Politecni La Fe
      • London, Storbritannia, NW1 2BU
        • Rekruttering
        • University College London Hospitals
      • Istanbul, Tyrkia (Türkiye), 34899
        • Rekruttering
        • Marmara University Pendik Training Hospital
      • Sakarya, Tyrkia (Türkiye), 54100
        • Rekruttering
        • Sakarya University Training and Research Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening
  • Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization
  • Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification
  • Have at least 1 target lesion (primary lung lesion or involved lymph node[s]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening
  • Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

Exclusion Criteria:

  • Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression
  • Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV
  • Another concurrent or prior primary malignancy within the last 36 months at informed consent
  • Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab
  • History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part 1: Cohort A and Cohort B

Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (cohort A: 22% gross tumor volume [GTV] and cohort B: 33% GTV) along with cCRT (concurrent chemotherapy with radiation therapy) followed by consolidation immunotherapy (cIT) to evaluate feasibility of JNJ-90301900 injection procedure.

JNJ-90301900 will be injected intratumorally and/or intranodally.

Durvalumab will be administered as intravenous (IV) infusion as cIT.

Radiation by intensity modulated radiation therapy (IMRT) will be administered.

Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.

Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.

Eksperimentell: Part 2: Arm A and Arm B

Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (Arm A: 22% GTV and Arm B: 33% GTV) along with cCRT followed by cIT to evaluate the efficacy and safety of JNJ-90301900.

JNJ-90301900 will be injected intratumorally and/or intranodally.

Durvalumab will be administered as intravenous (IV) infusion as cIT.

Radiation by intensity modulated radiation therapy (IMRT) will be administered.

Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.

Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.

Aktiv komparator: Part 2: Arm C: (Control treatment)

Participants will receive treatment with cCRT followed by cIT as control treatment to evaluate the efficacy and safety of JNJ-90301900.

Durvalumab will be administered as intravenous (IV) infusion as cIT.

Radiation by intensity modulated radiation therapy (IMRT) will be administered.

Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.

Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Objective Response Rate (ORR) Using Independent Central Review (ICR) Assessment
Tidsramme: Up to 2 Years and 2 months

ORR is defined as the percentage of participants who have a best response of complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1 using ICR assessments.

Up to 2 Years and 2 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Objective Response Rate (ORR) Post-cCRT and Pre-cIT
Tidsramme: Up to 12 Weeks

Objective response rate is defined as percentage of participants who achieve CR or PR, post-concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) and pre-consolidation immunotherapy (cIT) based on investigator's assessment according to RECIST v1.1.

Up to 12 Weeks
Disease Control Rate (DCR) Post-cCRT and Pre-cIT
Tidsramme: Up to 12 Weeks

DCR is defined as percentage of participants who achieve CR, PR and stable disease post-cCRT and pre-cIT based on investigator's assessment according to RECIST v1.1.

Up to 12 Weeks
Objective Response Rate (ORR) as Assessed by the Investigator
Tidsramme: Up to 2 Years and 2 months

ORR is defined as the percentage of participants who have a best response of CR or PR using RECIST v1.1 as assessed by the investigator.

Up to 2 Years and 2 months
Progression Free Survival (PFS)
Tidsramme: Up to 2 Years and 2 months

PFS is defined as the time from the enrollment/randomization until disease progression or death due to any cause according to RECIST v1.1.

Up to 2 Years and 2 months
Duration of Response (DoR)
Tidsramme: Up to 2 Years and 2 months

DoR will be calculated among responders from the date of initial documentation of a response to the date of first documented evidence of relapse according to RECIST v1.1, or death due to any cause, whichever occurs first.

Up to 2 Years and 2 months
Time to Locoregional Failure (LRF)
Tidsramme: Up to 2 Years and 2 months

Time to LRF is defined as the time from enrollment/randomization to the first LRF using ICR assessments.

Up to 2 Years and 2 months
Time to Distant Failure (DF)
Tidsramme: Up to 2 Years and 2 months

Time to DF is defined as the time from enrollment/randomization to the first DF using ICR assessments.

Up to 2 Years and 2 months
Number of Participants with Treatment-Emergent Adverse Event (TEAE) Related to Study Treatment
Tidsramme: Up to 2 Years and 2 months

TEAE is defined as any new or worsening adverse event (AE) occurring at or after the initial administration of study treatment through the day of last dose of study treatment received plus 30 days or prior to the start of subsequent anticancer therapy (non-durvalumab), whichever is earlier, or any follow-up AE with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent anticancer therapy, or any AE that is considered treatment-related regardless of the start date of the event. TEAEs related to JNJ-90301900 injection procedure, JNJ-90301900, RT, ChT, or cIT will be reported.

Up to 2 Years and 2 months
Number of Participants Reporting Laboratory Parameters, Physical Examination, Vital Signs Including Eastern Cooperative Oncology Group (ECOG) Performance Status Abnormalities
Tidsramme: Up to 2 Years and 2 months

Participants with laboratory parameters, physical examination, vital signs including ECOG performance status abnormalities will be reported.

Up to 2 Years and 2 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Johnson & Johnson Enterprise Innovation Inc. Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. desember 2024

Primær fullføring (Antatt)

31. desember 2028

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

30. oktober 2024

Først innsendt som oppfylte QC-kriteriene

30. oktober 2024

Først lagt ut (Faktiske)

31. oktober 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 90301900NSC2001
  • 90301900NSC2001 (Annen identifikator: Janssen Research & Development, LLC)
  • 2024-518276-32-00 (Registeridentifikator: EUCT number)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere